Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Key Points: Patients with both and variants exhibited poor renal prognosis compared with those with autosomal dominant Alport syndrome. The proportion of patients with digenic Alport syndrome was 1.7% among all patients with Alport syndrome.

Background: Digenic Alport syndrome could be associated with poor renal prognosis. However, the characteristics of patients with digenic Alport syndrome remain ambiguous.

Methods: We retrospectively investigated the clinical symptoms, pathological findings, genetic variants, and proportions of patients with digenic Alport syndrome. The ages at detection of proteinuria and development of ESKD were compared between patients with digenic Alport syndrome with disease-causing variants in and and those with autosomal dominant Alport syndrome (ADAS) previously analyzed by our group.

Results: Eighteen patients from nine families with digenic variants in and and four male and five female patients with digenic variants in and or were enrolled in this study. Next-generation sequencing revealed that the proportion of patients with digenic Alport syndrome was 1.7% among all patients with Alport syndrome. In patients with digenic variants in and , the median ages at detection of proteinuria and ESKD were 10.0 and 57.0 years, respectively. Compared with the patients with ADAS, the age at detection of proteinuria tended to be earlier (10.0 versus 20.0 years; = 0.073) and that at development of ESKD was significantly earlier (57.0 versus 72.0 years; = 0.045) in patients with digenic Alport syndrome.

Conclusions: Overall, patients with digenic Alport syndrome harboring and variants exhibited poor renal compared with the patients with ADAS. Therefore, timely identification of the two disease-causing variants is critical for the renal prognostic assessment and early treatment of patients with digenic Alport syndrome.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556934PMC
http://dx.doi.org/10.34067/KID.0000000000000547DOI Listing

Publication Analysis

Top Keywords

alport syndrome
48
patients digenic
44
digenic alport
40
patients
17
alport
14
digenic
13
syndrome
12
poor renal
12
detection proteinuria
12
compared patients
12

Similar Publications

Genome editing technologies, particularly clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, have transformed biomedical research by enabling precise genetic modifications. Due to its efficiency, cost-effectiveness and versatility, CRISPR has been widely applied across various stages of research, from fundamental biological investigations in preclinical models to potential therapeutic interventions. In nephrology, CRISPR represents a groundbreaking tool for elucidating the molecular mechanisms underlying kidney diseases and developing innovative therapeutic approaches.

View Article and Find Full Text PDF

Background: Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) and Alport syndrome are distinct glomerular diseases with different pathophysiologic mechanisms. Their coexistence is extremely rare and may present diagnostic and therapeutic challenges.

Case Presentation: A 42-year-old woman presented with persistent proteinuria and hematuria.

View Article and Find Full Text PDF

Alport syndrome is a hereditary glomerular disease driven by pathogenic variants in COL4A3-COL4A5 that compromise the α3-α4-α5 type IV collagen scaffold, manifesting as persistent hematuria, proteinuria, and ultimately end-stage renal disease. Its pronounced phenotypic variability, low sensitivity of renal biopsy, and limited response to ACE inhibitors complicate accurate diagnosis and therapy. In a cohort of 40 pedigrees from southwest China, we discovered 21 novel COL4A3-COL4A5 mutations.

View Article and Find Full Text PDF